IDENTIFICATION & CHARACTERISATION OF MOLECULAR DRIVERS OF THERAPEUTIC RESISTANCE
With
Professor Pieter Eichhorn
Group Leader, Curtin Medical Research Institute &
Dean of Research Infrastructure & Professor at Curtin University
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
He subsequently worked Dr. Jose Baselga at the Vall d’Hebron Institute of Oncology and Harvard Medical School contributing to studies on signalling networks, resistance mechanisms, and ubiquitin pathway regulation in cancer.
A major career highlight has been the identification and characterisation of molecular drivers of therapeutic resistance, including work on PI3K pathway biology and ubiquitin-regulated oncogenic signalling, published in high-impact journals and informing biomarker-driven therapeutic strategies.
At Curtin University, he has established and led a multidisciplinary translational research program focused on deubiquitinases, epithelial plasticity, and non-coding RNA biology in breast and melanoma. In parallel, he has provided strategic leadership as Dean of Research Infrastructure, overseeing major national and institutional infrastructure investments, NCRIS-aligned initiatives, and large-scale collaborative platforms that enhance research capability and clinical translation.
COLLABORATIONS
National University of Singapore, Walter and Eliza Hall Institute, Peter Mac, Vall d’Hebron, Helmholtz Munich, University of Manchester,
FUNDING
World Cancer Research Fund, Cancer Council Wa, Australia Center for RNA Therapy in Cancer
Source: Supplied
https://orcid.org/0000-0001-5840-943X
-
Novel therapies & next-gen medical devices in cardiovascular & vascular disease management
Professor Shirley Jansen AM is a distinguished vascular and endovascular surgeon whose career spans clinical leadership, academic excellence, and pioneering research. She currently holds the Lawrence-Brown Chair of Vascular Surgery at Curtin University’s School of Population Health and serves as Head of the Department of Vascular Surgery at Sir Charles Gairdner Hospital, a role she has held since 2015. In addition, she is the Director of the Heart & Vascular Research Institute at the Harry Perkins Institute for Medical Research. Her early career was marked by prestigious fellowships, including a British Heart Foundation Research Fellowship (1996), and multiple international travelling fellowships from leading surgical societies and industry sponsors between 2001 and 2002.
-
Big data research in maternal, perinatal and renal health epidemiology
Dr Erandi Hewawasam is a Research Fellow at the National Perinatal Epidemiology and Statistics Unit within the Centre for Big Data Research in Health at University of New South Wales (UNSW). Her work focuses on maternal and reproductive health, chronic diseases (e.g., kidney disease, endometriosis), and early-life outcomes. She is the Program Manager for the Fertility Medicine Data Asset for Australia (FM-DATA), an MRFF-funded national infrastructure project linking fertility, hospital, Medicare, pharmaceutical, and perinatal datasets covering more than 40 million individuals. She also coordinates the Early Life Course Platform, integrating around 20 New South Wales and Australian federal administrative datasets to support population health research.
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
